Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2020 00:13 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Dosing of First Patient in Phase I Study of Anti-TROP2 Antibody -TUB196 Conjugate

SHANGHAI, China, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and...
November 30, 2020 18:55 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006

SHANGHAI, China, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and...
October 07, 2020 22:50 ET | Source: Junshi Biosciences

Combination Study with JS016 and LY-CoV555 for Patients with Mild-to-Moderate COVID-19 Symptoms Met Primary and Secondary Endpoints

-- Viral load, symptoms, and hospitalizations or ER visits reduced -- Request for EUA and BLA filings for the combination therapy anticipated in Nov 2020 and as early as 2Q2021, respectively-- Large...
September 28, 2020 22:35 ET | Source: Junshi Biosciences

JUPITER-02 Phase III Global Study of Toripalimab at the Interim Analysis Met Pre-Specified Primary Endpoint of Progression-Free Survival in Recurrent or Metastatic Nasopharyngeal Carcinoma

SHANGHAI, China, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...
September 17, 2020 18:00 ET | Source: Junshi Biosciences

Junshi Biosciences Receives Orphan Drug Designation from the U.S. FDA for Toripalimab for the Treatment of Soft Tissue Sarcoma

SHANGHAI, China, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...
September 16, 2020 12:45 ET | Source: Junshi Biosciences

Junshi Biosciences and Wigen Biomedicine Enter Global Development and Commercialization Collaboration for Four Small Molecule Cancer Drug Candidates

SHANGHAI, China, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...
September 10, 2020 20:35 ET | Source: Junshi Biosciences

Junshi Biosciences Receives FDA Breakthrough Therapy Designation for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

SHANGHAI, China, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...
August 30, 2020 20:00 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Financial Results for Six Months Ended June 30, 2020 and Provides Corporate Updates

-- Supplemental NDAs for Toripalimab filed-- Expanding into infectious disease and collaborating with IMCAS and Lilly for COVID-19 neutralizing antibodies-- Dual Listing on the STAR Market SHANGHAI,...
August 20, 2020 10:45 ET | Source: Junshi Biosciences

Junshi Biosciences and Impact Therapeutics Establish Joint Venture to Develop PARP Inhibitor Senaparib (IMP4297) in China

SHANGHAI and NANJING, China, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery,...
August 09, 2020 22:07 ET | Source: Junshi Biosciences

TopAlliance Appoints Patricia Keegan, M.D., as Chief Medical Officer

ROCKVILLE, Md., Aug. 09, 2020 (GLOBE NEWSWIRE) -- TopAlliance Biosciences, a wholly own subsidiary of Shanghai Junshi Biosciences (HKEX: 1877; SSE: 688180) today announced the appointment of Dr....